<DOC>
	<DOC>NCT00784420</DOC>
	<brief_summary>The purpose of this study is to estimate the effect of steady state raltegravir on the steady state pharmacokinetics of UK-453,061 and steady state UK-453,061 on the steady state pharmacokinetics of raltegravir.</brief_summary>
	<brief_title>Drug Interaction Study Between Raltegravir And UK-453,061</brief_title>
	<detailed_description />
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive; Body Mass Index (BMI) of 18 to 30 kg/m2; and a total body weight &gt;50 kg (110 lbs). A BMI lower limit of 17.5 kg/m2 may be rounded up to 18.0 kg/m2; a BMI upper limit of 30.5 kg/m2 may be rounded down to 30.0 kg/m2 and will be acceptable for inclusion. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease; Treatment with an investigational drug within 30 days or 5 halflives (whichever is longer) preceding the first dose of study medication; Use of tobacco or nicotinecontaining products in excess of the equivalent of 5 cigarettes per day.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Drug Interaction, Pharmacokinetics</keyword>
</DOC>